A University of Turin psychiatrist, Valerio Ricci, and colleagues have reported that frequent cannabis use among adults receiving psychiatric care for non-psychotic conditions is linked to more mild psychotic-like experiences and depressive thoughts, with earlier initiation of use linked to greater symptom burden.
The researchers studied 150 adults aged 18 to 40 from Italian psychiatric clinics. Participants were split into three groups: heavy cannabis users (five or more days a week), occasional users (one to four times a month), and non-users. Each group was carefully screened to exclude anyone with a current or past psychotic disorder or a first‑degree relative with one, and self-reported drug use was confirmed with urine tests.
The heavy-use group comprised 43 individuals, the occasional group 47, and there were 60 non-users. Heavy users averages around 2.8 grams of cannabis daily, while occasional users consumed about 3.2 grams over a month. Smoking was the favoured method among heavy users, whereas vapourising was more common in the occasional group.
To gauge experiences and functioning, researchers employed the Community Assessment of Psychic Experiences scale to measure positive, negative and depressive symptoms, alongside standard life-skills assessments—the Global Assessment of Functioning and Clinical Global Impression scales.
Findings showed heavy cannabis users reported substantially higher scores for positive psychotic-like experiences than both the occasional users and non-users. They also reported more depressive symptoms, with the occasional group falling between the heavy users and non-users on these measures. The frequency of cannabis use correlated strongly with the severity of these specific experiences.
Initiation age mattered as well. Individuals who began using cannabis before the age of 16.4 years exhibited higher symptom scores than those who started later, and a longer overall duration of use followed a similar pattern.
The researchers explain the potential biological backdrop by noting that the brain’s endocannabinoid system—critical for mood, memory and perception—undergoes rapid development during adolescence. Introducing cannabinoids during this window may influence neurodevelopment.
Significantly, there were no statistically meaningful differences among the groups in negative symptoms such as avolition or emotional flattened affect. The researchers suggested standard symptom questionnaires might be insufficiently sensitive to capture subtle motivational deficits.
Daily functioning was notably poorer in the heavy cannabis group, with lower scores on overall well-being and daily living tasks compared with the other participants. Occasional users did not show the same level of impairment.
The study also identified a specific interaction with tobacco use. Heavy cannabis users who smoked tobacco daily reported higher positive symptom scores than those who used tobacco less frequently, a pattern not observed in other substances examined.
While tobacco can speed the body’s absorption of THC and both drugs activate reward pathways, the study emphasised that other substances such as alcohol, stimulants and hallucinogens did not independently predict the magnitude of psychotic-like experiences in their models.
As an observational cross‑sectional study, the researchers caution that causality cannot be established. It remains possible that individuals with mild symptoms turn to cannabis for relief, a self‑medication explanation consistent with the data. Self-reporting and other medications taken by some participants could also influence results.
Limitations include a lack of measurement of cannabis potency or specific chemical composition, something the authors note as a potential area for future research alongside longitudinal tracking to observe symptom trajectories over time.
The study, “Cannabis use patterns and psychotic-like experiences: a cross-sectional study of heavy users, occasional users, and non-users,” lists Valerio Ricci, Alessandro Sarni, Lorenzo Remondino, Marialuigia Barresi, Domenico De Berardis, Clara Cavallotto, Andrea Di Cesare, Vassilis Martiadis, Giovanni Martinotti and Giuseppe Maina as authors.
